<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469027</url>
  </required_header>
  <id_info>
    <org_study_id>CT-PAH 001</org_study_id>
    <nct_id>NCT00469027</nct_id>
  </id_info>
  <brief_title>Pulmonary Hypertension: Assessment of Cell Therapy</brief_title>
  <acronym>PHACeT</acronym>
  <official_title>Phase I Trial to Establish Safety of Autologous Progenitor Cell-based Gene Therapy Delivery of heNOS in Patients With Severe Pulmonary Arterial Hypertension(PAH)Refractory to Conventional Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northern Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to establish the safety of autologous progenitor cell-based gene
      therapy of heNOS in patients with severe Pulmonary Arterial Hypertension(PAH) refractory to
      conventional treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two centre, phase I clinical trial. A total of 18 patients will be studied using an
      open-label, dose escaling protocol; three patients will be entered into each of the five
      dosing panels. An additional three patients will be entered into the final dose panel to
      establish safety at the maximum tolerated dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoints will be related to the tolerability and safety of injection of genetically engineered progenitor cells in patients with severe PAH.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Potential efficacy of this approach will be assessed by changes in hemodynamic pressures, patient perceived quality of life and exercise capacity</measure>
    <time_frame>3 month post cell delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>eNOS transfected EPCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eNOS transfected EPCs will be delivered by injection via a PA line, incremental doses over three days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>eNOS transfected EPCs will be delivered via a PA line</intervention_name>
    <description>incremental dosing over 3 days</description>
    <arm_group_label>eNOS transfected EPCs</arm_group_label>
    <other_name>eNOS transfect EPCs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of idiopathic Pulmonary Arterial Hypertension

          -  Familial PAH or anorexigen induced PAH

          -  Specified 6-minute walk distance

        Exclusion Criteria:

          -  Intra or extra cardiac communication between the right and left sided circulations

          -  Hemodynamic instability

          -  Left ventricular ejection fraction &lt; 40%

          -  Thromboembolic event or recent hospitalization for worsening right sided heart failure
             in past 3 months

          -  CVP&gt;20mmHg at time of research heart catheterization

          -  Pregnancy

          -  Concurrent hepatitis or HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Granton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital and University Health Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Langleben, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir Mortimer B. Davis - Jewish General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis - Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension (PAH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

